Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramIn the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
- SASSAS, NC State Launch AI Think & Do Tank to Advance Health ResearchResearch partnership applies data and AI to speed the path to new treatments and strengthen nutrition and environmental resilience — Fifty years after SAS grew out of an agricultural research project at North Carolina State University, the two...
- Curaleaf InternationalCuraleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New ZealandCuraleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic...
- Medicenna Therapeutics Corp. TORONTO andMedicenna Announces Results of Annual General and Special Meeting of ShareholdersMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).
- Axogen, Inc.Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve RepairAxogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.
- MedStar HealthNew Breast Cancer Survey Shows Concern not Always Leading to Screening in Women 40 and Over, According to MedStar HealthA new national survey from MedStar Health reveals that three in four women are concerned about developing breast cancer in their lifetime, yet less than half of women over 40 are getting regular mammograms—and more than eight in 10 say they...
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
- CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell TherapiesCaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS)...
- Numinus Wellness Inc.Numinus Wellness Founders to Resume Original Executive RolesNuminus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that its founders will resume their original executive leadership roles, effective October 1, 2026.Payton Nyquvest, founder and Executive Chair, will return to the role of Chief Executive Officer...
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
- Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded WarrantsSagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering were sold by Sagimet.
- Adventist HealthCareAdventist HealthCare Names Opal Howard Senior Vice President and Chief Human Resources OfficerAdventist HealthCare today announced the appointment of Opal Howard as Senior Vice President and Chief Human Resources Officer. Howard will serve as a member of the health system's senior leadership team and lead human resources strategies...